[Chronic myeloid leukemia treatment and human immunodeficiency virus infection]

Rev Clin Esp (Barc). 2014 May;214(4):231-2. doi: 10.1016/j.rce.2014.01.025. Epub 2014 Feb 22.

[Article in Spanish]

Authors

D Campillo-Recio¹, L Perez-Rodriguez², E Yebra², M Cervero-Jimenez²

Affiliations

¹ Servicio de Medicina Interna, Hospital Severo Ochoa, Leganés, Madrid, España. Electronic address: [email protected].
² Servicio de Medicina Interna, Hospital Severo Ochoa, Leganés, Madrid, España.

PMID: 24564991
DOI: 10.1016/j.rce.2014.01.025

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anti-HIV Agents / adverse effects
Anti-HIV Agents / therapeutic use*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Benzamides / adverse effects
Benzamides / therapeutic use
Drug Interactions
HIV Infections / complications*
HIV Infections / drug therapy
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Male
Piperazines / adverse effects
Piperazines / therapeutic use
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / adverse effects
Pyrimidines / therapeutic use
Treatment Outcome

Substances

Anti-HIV Agents
Antineoplastic Agents
Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate